| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Circulation, Vol 75, 213-220, Copyright © 1987 by American Heart Association
H Sato, M Inoue, T Matsuyama, H Ozaki, T Shimazu, H Takeda, Y Ishida and T Kamada
A new cardioselective beta 1-adrenoceptor partial agonist, xamoterol, has
been developed for the treatment of heart failure, especially that
associated with ischemic heart disease. To investigate the hemodynamic
effect of xamoterol in relation to sympathetic nervous activity,
hemodynamic variables and plasma norepinephrine (NE) levels were measured
at rest and during three graded bicycle exercise tests before and after a
single intravenous dose of 0.15 mg/kg xamoterol in 10 patients with
mild-to-moderate left ventricular dysfunction. Plasma NE increased with
increasing grade of exercise and a linear correlation between plasma NE and
heart rate was observed at four time points (at rest and three exercise
levels) before and after xamoterol. After administration of xamoterol, the
slope of the regression line of plasma NE-heart rate relation was
significantly less steep than that before drug. Predose and postdose
regression lines crossed at 440 pg/ml of plasma NE. Similar effects were
observed on the plasma NE-cardiac index and plasma NE-systolic blood
pressure relations (regression lines crossed at 380 and 530 pg/ml of plasma
NE, respectively). Thus, xamoterol had a dual agonist-antagonist effect in
relation to plasma NE, and the crossover point lay approximately between
400 pg/ml and 500 pg/ml. This level of plasma NE was achieved at a low
exercise level and at a heart rate of about 100 beats/min. These results
indicate that xamoterol has intrinsic sympathomimetic activity comparable
to relatively low sympathetic activity (400 to 500 pg/ml of plasma NE) and
therefore acts as a beta 1-agonist when sympathetic nervous activity is
below this level and as an antagonist when sympathetic activity is above
this level.
ARTICLES
Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction
This article has been cited by other articles:
![]() |
M Morikawa, H Sato, H Sato, Y Koretsune, Y Ohnishi, T Kurotobi, T Kuzuya, and M Hori Sustained left ventricular diastolic dysfunction after exercise in patients with dilated cardiomyopathy Heart, September 1, 1998; 80(3): 263 - 269. [Abstract] [Full Text] |
||||
![]() |
H. Funaya, M. Kitakaze, K. Node, T. Minamino, K. Komamura, and M. Hori Plasma Adenosine Levels Increase in Patients With Chronic Heart Failure Circulation, March 18, 1997; 95(6): 1363 - 1365. [Abstract] [Full Text] |
||||
![]() |
K. Node, M. Kitakaze, H. Kosaka, K. Komamura, T. Minamino, M. Inoue, M. Tada, M. Hori, and T. Kamada Increased Release of NO During Ischemia Reduces Myocardial Contractility and Improves Metabolic Dysfunction Circulation, January 15, 1996; 93(2): 356 - 364. [Abstract] [Full Text] |
||||
![]() |
M. Kitakaze, T. Minamino, K. Node, K. Komamura, Y. Shinozaki, H. Mori, H. Kosaka, M. Inoue, M. Hori, and T. Kamada Beneficial Effects of Inhibition of Angiotensin-Converting Enzyme on Ischemic Myocardium During Coronary Hypoperfusion in Dogs Circulation, August 15, 1995; 92(4): 950 - 961. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1987 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |